Angiotensin-converting enzyme inhibition attenuates proteinuria and renal TGF-β1 mRNA expression in rats with chronic renal disease

Pharmacology

Volumn 57, Issue 1, 1998, Pages 20-27

  Ali, Shujath M ^a   Laping, Nicholas J ^a   Fredrickson, Todd A ^a   Contino, Lisa C ^a   Olson, Barbara A ^a   Anderson, Karen ^a   Brooks, David P ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b SB Pharmaceuticals   (United States)

Author keywords

Angiotensin II; Angiotensin converting enzyme inhibitor; Chronic renal disease; Transforming growth factor beta 1

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA; PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFECT; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLOMERULOSCLEROSIS; NEPHRECTOMY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOTTING, NORTHERN; CAPTOPRIL; DISEASE MODELS, ANIMAL; GENE EXPRESSION; KIDNEY; KIDNEY CORTEX; KIDNEY FAILURE, CHRONIC; NEPHRECTOMY; PEPTIDYL-DIPEPTIDASE A; PROTEINURIA; RATS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031838551     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028222     Document Type: Article

References (37)

1. Sporn MB, Roberts AB, Wakefield LB, de Crombrugghe B: Some recent advances in the chemistry and biology of transforming growth factor beta. J Cell Biol 1987;105:1039-1045.
2. Roberts AM, Sporn MB: Transforming growth factor beta. Adv Cancer Res 1988;51:107-145.
3. Roberts AM, McCune BK, Sporn MB: Transforming growth factor beta: Regulation of extracellular matrix. Kidney Int 1992;41:557-559.
4. Finch CE, Laping NJ, Morgan TE, Nichols NR, Pasinetti GM: TGF-β1 is an organizer of responses to neurodegeneration. J Cell Biochem 1993;53:314-322.
5. Pierce GF, Van de Berg J, Rudolph R, Tarpley J, Mustoe TA: Platelet-derived growth factor BB and transforming growth factor beta 1 selectively modulate glycosaminoglycans, collagen, and myofibroblasts in excisional wounds. Am J Pathol 1991;138:629-646.
6. Derynck R, Jarrett JA, Chen EY, Goeddel DV: The murine TGFβ precursor. J Biol Chem 1986;261: 4377-4379.
7. Centrella M, Canalis E: Transforming and nontransforming growth factor are present in medium conditioned by fetal rat calvarie. Proc Natl Acad Sci USA 1985;82:7335-7339.
8. Frolik CA, Dart LL, Meyers CA, Smith DM, Sporn MB: Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci USA 1983;80:3676-3680.
9. Roberts AB, Anzano MA, Meyers CA, Wideman J, Blacher R, Pan YC, Stein S, Lehrman SR, Smith JM, Lamb LC: Purification and properties of transforming growth factor beta from bovine kidney. Bio-chemistry 1983;22:5692-5698.
10. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs. hyperplasia: Autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456-461.
11. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracclluar matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.
12. Mayer G, Lafayette RA, Oliver J, Deen WM, Myers BD, Meyer TW: Effects of angiotensin II receptor blockade on remnant glomerular permselectivity. Kidney Int 1993; 43:346-353.
13. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, Bertani T, Remuzzi G: Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993;4:40-49.
14. Morelli E, Loon N, Meyer TW, Peters W, Myers BD: Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990;39:76-82.
15. Davidsohn L, Henry JB: Clinical Diagnosis by Laboratory Methods, ed 14. Philadelphia, Saunders, 1969, p 48.
16. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem 1987;162:156-159.
17. Aviv H, Leder P: Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. Proc Natl Acad Sci USA 1972;69:1408-1412.
18. Edwards RM: Segmental effects of norepinephrine and angiotensin II on isolated renal microvessels. Am J Physiol 1983;244:F526-F534.
19. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;7:1993-2000.
20. Yoshida Y, Kawamura T, Okoma M, Fogo A, Ichikawa I: Effects of antihypertensive drugs on glomerular morphology. Kidney Int 1989; 36:626-635.
21. Fisher SE, Absher M: Norepinephrine and ANGII stimulate secretion of TGF-β by neonatal rat cardiac fibroblasts in vitro. Am J Physiol 1995;268:C910-C917.
22. Brooks DP, Contino LC, Short BS, Gowan C, Trizna W, Edwards RM: SB 203220: A novel angiotensin II receptor antagonist and renoprotective agent. J Pharmacol Exp Ther 1995;274:1222-1227.
23. Sharma K, Ziyadeh FN: The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol 1994;266:F829-F842.
24. Okuda S, Languino LR, Ruoslahti E, Border WA: Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 1990;86:453-462.
25. Border WA, Okuda S, Languino LR, Ruoslahti E: Transforming growth factor-β regulates production of proteoglycans by mesangial cells. Kidney Int 1990;37:689-695.
26. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor-β1. Nature 1990;346:371-374.
27. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992;360:361-364.
28. Obberghen-Scheilling EV, Roche NS, Flanders KC, Sporn MB, Roberts AB: Transforming growth factor β1 positively regulates its own expression in normal and transformed cells. J Biol Chem 1988;263: 7741-7746.
29. Kim S-J, Jeang KT, Glick AB, Sporn MB, Roberts AB: Promoter sequences of the human transforming growth factor-β1 gene responsive to transforming growth factor-β1 autoinduction. J Biol Chem 1989;264: 7041-7045.
30. Kim S-J, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, Roberts AB: Autoinduction of transforming growth factor-β1 is mediated by the AP-1 complex. Mol Cell Biol 1990;10:1492-1497.
31. Pimentel JL Jr, Sundell CL, Wang S, Kopp JB, Montera A, Martinez-Maldonado M: Role of angiotensin II in the expression and regulation of transforming growth factor-β in obstructive nephropathy. Kidney Int 1995;42:1233-1246.
32. Angel P, Michael K: The role of jun, fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072: 129-157.
33. Omiya T, Yamauchi T, Ogura T, Asanuma M, Ota Z: Angiotensin II induces in vivo c-fos expression from rat renal cortex and medulla. Renal Physiol Biochem 1995;18: 81-88.
34. Curran T, Franza BR Jr: Fos and jun: The AP-1 connection. Cell 1988;55:395-397.
35. López-Casillas F, Wrana JL, Massague J: Betaglycan presents ligand to the TGF-β signaling receptor. Cell 1993;73:1435-1444.
36. Ebner R, Chen RH, Shum L, Lawler S, Zioncheck TF, Lee A, López AR, Derynck R: Cloning of a type I TGF-β receptor and its effect on TGF-β binding to the type II receptor. Science 1993;260:1344-1348.
37. Massague J: TGFβ signaling: Receptors, transducers, and mad proteins. Cell 1996;85:947-950.